Pan Cytokeratin Monoclonal Antibody (AE1/AE3), eFluor™ 570, eBioscience | Invitrogen 41-9003-80 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Pan Cytokeratin Monoclonal Antibody (AE1/AE3), eFluor™ 570, eBioscience

catalog :

41-9003-80

quantity :

25 µg

price :

US 169.00

clonality :

monoclonal

host :

mouse

conjugate :

eFluor 570

clone name :

AE1/AE3

reactivity :

human, mouse, dogs, domestic rabbit, rhesus macaque

application :

immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section

more info or order :

Invitrogen product webpage

citations: 26

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry - paraffin section; human immunohistochemistry; human	Lin J, Izar B, Wang S, Yapp C, Mei S, Shah P, et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. elife. 2018;7: pubmed publisher
	Zhang X, Ekanayake Weeramange C, Hughes B, Vasani S, Liu Z, Warkiani M, et al. Application of circulating tumour cells to predict response to treatment in head and neck cancer. Cell Oncol (Dordr). 2022;45:543-555 pubmed publisher
	Brylka L, J xe4 hn Rickert K, Baranowsky A, Neven M, Horn M, Yorgan T, et al. Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells. Cancers (Basel). 2022;14: pubmed publisher
	Delalande J, Nagy N, McCann C, Natarajan D, Cooper J, Carreno G, et al. TALPID3/KIAA0586 Regulates Multiple Aspects of Neuromuscular Patterning During Gastrointestinal Development in Animal Models and Human. Front Mol Neurosci. 2021;14:757646 pubmed publisher
	Loreth D, Schuette M, Zinke J, Mohme M, Piffko A, Schneegans S, et al. CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. Int J Mol Sci. 2021;22: pubmed publisher
	Pinto F, Santos Ferreira L, Pinto M, Gomes C, Reis C. The Extracellular Small Leucine-Rich Proteoglycan Biglycan Is a Key Player in Gastric Cancer Aggressiveness. Cancers (Basel). 2021;13: pubmed publisher
	Bartkowiak K, Heidrich I, Kwiatkowski M, Gorges T, Andreas A, Geffken M, et al. Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells. Cancers (Basel). 2021;13: pubmed publisher
	Wheeler D, Takebe N, Hinoue T, Hoadley K, Cardenas M, Hamilton A, et al. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021;39:38-53.e7 pubmed publisher
	Tahkola K, Ahtiainen M, Kellokumpu I, Mecklin J, Laukkarinen J, Laakkonen J, et al. Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer. Virchows Arch. 2021;478:209-217 pubmed publisher
	Desai N, Neyaz A, Szabolcs A, Shih A, Chen J, Thapar V, et al. Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. Nat Commun. 2020;11:6319 pubmed publisher
	Liu H, Vuppalapaty M, Wilkerson C, Renier C, Chiu M, Lemaire C, et al. Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. Front Oncol. 2020;10:572895 pubmed publisher
	Raimondi L, Raimondi F, Di Benedetto L, Cimino G, Spinelli G. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer. Int J Mol Sci. 2020;21: pubmed publisher
	Tamminga M, Oomens L, Hiltermann T, Andree K, Tibbe A, Broekmaat J, et al. Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients. Transl Lung Cancer Res. 2020;9:1093-1100 pubmed publisher
	Zhang K, Fang X, Zhu J, Yang R, Wang Y, Zhao W, et al. Effective Reconstruction of Functional Urethra Promoted With ICG-001 Delivery Using Core-Shell Collagen/Poly(Llactide-co-caprolactone) [P(LLA-CL)] Nanoyarn-Based Scaffold: A Study in Dog Model. Front Bioeng Biotechnol. 2020;8:774 pubmed publisher
	Koch C, Kuske A, Joosse S, Yigit G, Sflomos G, Thaler S, et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med. 2020;12:e11908 pubmed publisher
	Riebensahm C, Joosse S, Mohme M, Hanssen A, Matschke J, Goy Y, et al. Clonality of circulating tumor cells in breast cancer brain metastasis patients. Breast Cancer Res. 2019;21:101 pubmed publisher
	Stevens M, Oomens L, Broekmaat J, Weersink J, Abali F, Swennenhuis J, et al. VyCAP's puncher technology for single cell identification, isolation, and analysis. Cytometry A. 2018;93:1255-1259 pubmed publisher
	Nanou A, Crespo M, Flohr P, de Bono J, Terstappen L. Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles. Cancers (Basel). 2018;10: pubmed publisher
	Castro J, Sanchez L, Nunez M, Lu M, Castro T, Sharifi H, et al. Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2). Dis Markers. 2018;2018:4653109 pubmed publisher
	Di Pompo G, Lemma S, Canti L, Rucci N, Ponzetti M, Errani C, et al. Intratumoral acidosis fosters cancer-induced bone pain through the activation of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinoma. Oncotarget. 2017;8:54478-54496 pubmed publisher
	Donnenberg V, Huber A, Basse P, Rubin J, Donnenberg A. Neither epithelial nor mesenchymal circulating tumor cells isolated from breast cancer patients are tumorigenic in NOD-scid Il2rgnull mice. NPJ Breast Cancer. 2016;2:16004 pubmed publisher
	Toki M, Carvajal Hausdorf D, Altan M, McLaughlin J, Henick B, Schalper K, et al. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. J Thorac Oncol. 2016;11:1901-1911 pubmed publisher
	Li Y, Adomat H, Guns E, Hojabrpour P, Duronio V, Curran T, et al. Identification of a Hematopoietic Cell Dedifferentiation-Inducing Factor. J Cell Physiol. 2016;231:1350-63 pubmed publisher
	Shi G, Cui W, Mukthavaram R, Liu Y, Simberg D. Binding and isolation of tumor cells in biological media with perfluorocarbon microbubbles. Methods. 2013;64:102-7 pubmed publisher
	Donnenberg A, Zimmerlin L, Landreneau R, Luketich J, Donnenberg V. KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients. PLoS ONE. 2012;7:e52885 pubmed publisher
	Donnenberg V, Landreneau R, Pfeifer M, Donnenberg A. Flow cytometric determination of stem/progenitor content in epithelial tissues: an example from nonsmall lung cancer and normal lung. Cytometry A. 2013;83:141-9 pubmed publisher

product information

Product Type :

Antibody

Product Name :

Pan Cytokeratin Monoclonal Antibody (AE1/AE3), eFluor™ 570, eBioscience

Catalog # :

41-9003-80

Quantity :

25 µg

Price :

US 169.00

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Canine, Human, Mouse, Non-human primate, Rabbit, Rhesus Monkey

Applications :

Immunocytochemistry: 1 µg/mL, Immunohistochemistry (Frozen): Assay-Dependent, Immunohistochemistry (Paraffin): Assay-Dependent

Species :

Canine, Human, Mouse, Non-human primate, Rabbit, Rhesus Monkey

Clone :

AE1/AE3

Isotype :

IgG1

Storage :

4° C, store in dark, DO NOT FREEZE!

Description :

Cytokeratin pan is part of a subfamily of intermediate filament proteins that are characterized by remarkable biochemical diversity, and represented in human epithelial tissues by at least 20 different polypeptides. Cytokeratins range in molecular weight between 40 kDa- 68 kDa, and an isoelectric pH between 4.9-7.8. The individual human cytokeratins are numbered 1 to 20. The various epithelia in the human body usually express cytokeratins which are not only characteristic of the type of epithelium, but also related to the degree of maturation or differentiation within an epithelium. Cytokeratin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeratin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays. The composition of cytokeratin pairs vary with the epithelial cell type, stage of differentiation, cellular growth environment, and disease state. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1 µg/mL, Immunohistochemistry (Frozen): Assay-Dependent, Immunohistochemistry (Paraffin): Assay-Dependent

Aliases :

2310016L08Rik; 3300001P10Rik; 39.1; 40-kDa keratin intermediate filament; 47 kDa cytokeratin; 56 kDa cytokeratin; 57kd keratin; 57kDa keratin; 58 kDa cytokeratin; 60-kDa keratin; 63kDa Keratin; 65 kDa cytokeratin; 67 kDa cytokeratin; AA960620; adult keratin; AI324768; AI528832; AI626930; AI663979; AL022697; alpha keratin; AU019895; AW108092; AW146334; basic epidermal type II cytokeratin (carboxy-terminal region, clone pUF164); BB005427; BCIE; BIE; Card2; cell proliferation-inducing gene 46 protein; CK 2e; CK1; CK-1; CK10; CK-10; CK13; CK-13; CK14; CK-14; CK15; CK-15; CK16; CK-16; CK-17; CK18; CK-18; CK19; CK-19; CK-1B; CK-2e; CK3; CK-3; CK4; CK-4; CK5; CK-5; ck55; CK6A; CK-6A; CK6C; CK-6C; CK6D; CK-6D; CK-6E; CK7; CK-7; CK8; CK-8; CYK18; CYK4; CYK8; CYKER; cytokeratin 1; cytokeratin 10; cytokeratin 13; cytokeratin 14; cytokeratin 15; cytokeratin 16; cytokeratin 18; cytokeratin 19; cytokeratin 3; cytokeratin 4; cytokeratin 5; cytokeratin 6A; cytokeratin 6C; cytokeratin 6D; cytokeratin 7; cytokeratin 8; cytokeratin 8 (370 AA); cytokeratin endo A; Cytokeratin endo B; cytokeratin otokeratin; cytokeratin type II; cytokeratin type II, component Ib/c; cytokeratin type II, component III; cytokeratin VIB; cytokeratin VII; cytokeratin-1; Cytokeratin-10; cytokeratin-13; Cytokeratin-14; cytokeratin-15; Cytokeratin-16; cytokeratin-17; Cytokeratin-18; cytokeratin-19; Cytokeratin-1B; Cytokeratin-2e; cytokeratin-3; Cytokeratin-4; cytokeratin-5; Cytokeratin-6A; cytokeratin-6B; cytokeratin-6C; Cytokeratin-6D; cytokeratin-6E; cytokeratin-7; Cytokeratin-8; cytokeratin-A; Cytoskeletal 57 kDa keratin; D130054E02Rik; D15Wsu77e; DDD; DDD1; ear specific cytokeratin; EBS2; ebs3; ebs4; EGK_03684; EGK_03685; EHK; EHK1; Endo B; EndoA; EndoC; epidermal keratin 10; epidermal keratin VII; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; epidermolysis bullosa simplex, Dowling-Meara, Koebner; epidermolytic hyperkeratosis 1; epidermolytic hyperkeratosis; keratosis palmaris et plantaris; epithelial keratin 1; epithelial keratin 10; epithelial keratin 2e; Epithelial keratin-1; Epithelial keratin-2e; EPPK; fgk; fin and gill keratin; FNEPPK; focal non-epidermolytic palmoplantar keratoderma; GK-19; Hair alpha protein; HMWCK; Hom s 5; I79_019823; I79_021074; I79_023185; I79_024335; intermediate filament protein; K1; K10; K13; K14; K15; K16; K17; K18; K19; K1B; K1C1; K1CO; K1CP; K1CS; K2C7; K2C8; K2e; K3; K3 keratin; K4; K5; K6A; K6a keratin; K6C; K6D; K7; K77; K8; Ka10; Ka13; Ka14; Ka15; Ka16; Ka17; Ka19; kamp-keratin derived antimicrobial peptide; Kb1; Kb2; Kb4; Kb7; KDAMP; KER1; Ker10; Ker2; KERA; keratin; keratin 1; keratin 1 (epidermolytic hyperkeratosis); keratin 1, type II; keratin 10; keratin 10 (epidermolytic hyperkeratosis); keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris); keratin 10, type I; keratin 10, type I L homeolog; keratin 10, type I S homeolog; keratin 12, gene 2 S homeolog; keratin 13; keratin 13, type I; keratin 13, type I S homeolog; keratin 14; keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner); keratin 14, type I; keratin 14, type I L homeolog; keratin 15; keratin 15, gene 1 S homeolog; keratin 15, type I; keratin 16; keratin 16 (focal non-epidermolytic palmoplantar keratoderma); keratin 16, type I; keratin 16, type I S homeolog; keratin 17; keratin 17 L homeolog; keratin 17, type I; keratin 17, type I L homeolog; keratin 18; keratin 18, type I; keratin 19; keratin 19 S homeolog; keratin 19 S homeolog; keratin 19; keratin 19, type I; Keratin 1B; keratin 2; keratin 2 (epidermal ichthyosis bullosa of Siemens); keratin 2 epidermis; keratin 2, type II; keratin 24; keratin 2A; keratin 2A (epidermal ichthyosis bullosa of Siemens); keratin 3; keratin 3, type II; keratin 4; keratin 4, type II; keratin 5; keratin 5 (epidermolysis bullosa simplex Dowling-Meara/Kobner/Weber-Cockayne types); keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types)

more info or order :

Invitrogen product webpage